| 摘要: |
| 目的：研究依达拉奉联合中成药制剂对急性脑梗死大鼠的疗效比较和安全性评价。方法：将SD大鼠随机分为假手术组、模型组、依达拉奉联合丹红注射液组（A组）、依达拉奉联合血塞通冻干组（B组）、依达拉奉联合醒脑静组（C组）、依达拉奉联合疏血通注射液组（D组），采用线栓法制作大鼠左侧大脑中动脉脑缺血（MCAO）模型，除假手术组外，每组按不同时间点（1、3、5、7d）分为4个亚组，术后各组腹腔注射相应药物，1次/d，分别连续给药1、3、5、7d，模型组、假手术组予以等体积0.9%氯化钠注射液灌胃，观察比较各组大鼠各时间点神经功能缺损评分、脑组织水含量、脑组织梗死体积、安全性评价指标等。结果：模型组与假手术组各时间点的神经功能缺损评分、脑组织水含量、脑组织梗死体积及安全性评价指标中WBC计数、APTT时间比较，差异均具有统计学意义(P＜0.01)；与模型组比较，A、B、C、D组各时间点的神经功能缺损评分及3、5、7d脑组织水含量、脑梗死体积及安全性评价指标中白细胞（WBC）计数、活化部分凝血酶原（APTT）时间均降低，差异均有统计学意义(P＜0.05或P＜0.01)。结论：依达拉奉联合中成药制剂治疗急性脑梗死大鼠疗效显著、可靠安全，并且随治疗时间延长，对缺血缺氧神经元的改善作用越明显。 |
| 关键词: 脑梗死 依达拉奉 丹红注射液 血塞通 醒脑静注射液 疏血本通注射液 实验研究 |
| DOI： |
|
|
| Clinical effect and safety of edaravone combined with Chinese patent drugs in treatment of rats with acute cerebral infarction |
| FENG Junjian,ZHOU Desheng |
| (Hunan University of Chinese Medicine，Changsha 410208，Hunan，China;The First Affiliated Hospital of Hunan University of Chinese Medicine，Changsha 410007，Hunan，China) |
| Abstract: |
| Objective：To investigate the clinical effect and safety of edaravone combined with Chinese patent drugs in the treatment of rats with acute cerebral infarction.Methods：Sprague-Dawley rats were randomly divided into sham-operation group，model group，edaravone+Danhong injection group (group A)，edaravone+Xuesaitong (freeze-dried) group (group B)，edaravone+Xingnaojing group (group C)，and edaravone+Shuxuetong injection group (group D).The suture method was used to establish a rat model of left middle cerebral artery occlusion.All groups except the sham-operation group were further divided into 4 subgroups according to the time points of 1，3，5，and 7 days.The corresponding drug was given by intraperitoneal injection，once a day for 1，3，5，and 7 days，respectively，and the rats in the model group and the sham-operation group were given an equal volume of 0.9% sodium chloride injection by gavage.The groups were compared in terms of neurological deficit score，brain water content，cerebral infarct volume，and safety assessment indices at each time point.Results：There were significant differences between the model group and the sham-operation group in neurological deficit score，brain water content，cerebral infarct volume，and the safety assessment indices of white blood cell count (WBC) and activated partial thromboplastin time (APTT) at each time point (P＜0.01).Compared with the model group，groups A，B，C，and D had a significant reduction in neurological deficit score at each time point，as well as significant reductions in brain water content，cerebral infarct volume，and the safety assessment indices of WBC and APTT on days 3，5，and 7 (P＜0.05 or P＜0.01).Conclusion：Edaravone combined with Chinese patent drugs has good clinical effect and safety in the treatment of rats with acute cerebral infarction and can improve ischemic/hypoxic neurons in a time-dependent manner. |
| Key words: cerebral infarction edaravone Danhong injection Xuesaitong Xingnaojing injection Shuxuetong injection experimental study |
